Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

contributed by Agilent | 10/05/2023

With Agilent SureSelect Cancer Tumor-Specific assays, focused cancer NGS panels comprised of approximately 50 genes each, you can detect key classes of somatic alterations (SNVs, CNVs, indels, DNA translocations) from lung, colon, pancreas, kidney, and bladder tissue samples. For de novo gene fusion detection, the modular workflow allows the option to combine a SureSelect Cancer Tumor-Specific DNA assay with SureSelect Cancer CGP RNA assay (80 genes) in the same sequencing run. Obtain high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimal sample input. Workflows are configurable with options to incorporate sample QC, automation, and data analysis solutions.

>> Download Data Sheet as a PDF

Find out more on Agilent's website here

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.